Anchor Funding Administration LLC lower its stake in Laboratory Co. of America Holdings (NYSE:LH – Free Report) by 66.6% throughout the 2nd quarter, in response to its most up-to-date Type 13F submitting with the Securities and Trade Fee (SEC). The institutional investor owned 4,277 shares of the medical analysis firm’s inventory after promoting 8,521 shares throughout the interval. Anchor Funding Administration LLC’s holdings in Laboratory Co. of America had been price $870,000 on the finish of the newest reporting interval.
A number of different institutional buyers have additionally not too long ago added to or lowered their stakes in LH. Financial institution of New York Mellon Corp raised its holdings in Laboratory Co. of America by 135.0% within the second quarter. Financial institution of New York Mellon Corp now owns 1,609,826 shares of the medical analysis firm’s inventory valued at $327,616,000 after buying an extra 924,881 shares within the final quarter. Allspring World Investments Holdings LLC raised its holdings in shares of Laboratory Co. of America by 58.8% throughout the first quarter. Allspring World Investments Holdings LLC now owns 1,613,854 shares of the medical analysis firm’s inventory price $352,563,000 after buying an extra 597,571 shares throughout the interval. Diamond Hill Capital Administration Inc. raised its holdings in shares of Laboratory Co. of America by 25.4% throughout the second quarter. Diamond Hill Capital Administration Inc. now owns 1,949,640 shares of the medical analysis firm’s inventory price $396,771,000 after buying an extra 395,197 shares throughout the interval. Choose Fairness Group L.P. acquired a brand new stake in shares of Laboratory Co. of America throughout the second quarter price $73,928,000. Lastly, Veritas Funding Companions UK Ltd. raised its holdings in shares of Laboratory Co. of America by 32.5% throughout the fourth quarter. Veritas Funding Companions UK Ltd. now owns 1,140,300 shares of the medical analysis firm’s inventory price $259,133,000 after buying an extra 279,628 shares throughout the interval. 95.94% of the inventory is owned by institutional buyers and hedge funds.
Laboratory Co. of America Inventory Efficiency
Shares of LH opened at $215.07 on Friday. The agency has a 50-day transferring common value of $224.27 and a 200 day transferring common value of $211.88. The agency has a market capitalization of $18.13 billion, a PE ratio of 43.27, a P/E/G ratio of 1.74 and a beta of 1.06. The corporate has a fast ratio of 0.77, a present ratio of 0.88 and a debt-to-equity ratio of 0.39. Laboratory Co. of America Holdings has a 52-week low of $191.97 and a 52-week excessive of $238.46.
Laboratory Co. of America (NYSE:LH – Get Free Report) final introduced its earnings outcomes on Thursday, August 1st. The medical analysis firm reported $3.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.78 by $0.16. The agency had income of $3.22 billion throughout the quarter, in comparison with analyst estimates of $3.19 billion. Laboratory Co. of America had a internet margin of three.60% and a return on fairness of 15.39%. Laboratory Co. of America’s income was up 6.2% in comparison with the identical quarter final yr. Throughout the identical quarter within the prior yr, the agency posted $3.42 EPS. On common, sell-side analysts anticipate that Laboratory Co. of America Holdings will publish 14.61 earnings per share for the present fiscal yr.
Laboratory Co. of America Declares Dividend
The agency additionally not too long ago disclosed a quarterly dividend, which was paid on Friday, September thirteenth. Stockholders of file on Thursday, August twenty ninth got a dividend of $0.72 per share. The ex-dividend date of this dividend was Thursday, August twenty ninth. This represents a $2.88 annualized dividend and a dividend yield of 1.34%. Laboratory Co. of America’s dividend payout ratio (DPR) is 57.95%.
Insider Exercise
In different information, EVP Lance Berberian bought 12,093 shares of the agency’s inventory in a transaction dated Monday, August fifth. The shares had been bought at a median value of $229.10, for a complete transaction of $2,770,506.30. Following the completion of the transaction, the chief vice chairman now owns 15,921 shares within the firm, valued at roughly $3,647,501.10. The transaction was disclosed in a authorized submitting with the SEC, which is accessible by way of the SEC web site. In different Laboratory Co. of America information, Director Kerrii B. Anderson bought 586 shares of the corporate’s inventory in a transaction dated Thursday, August eighth. The shares had been bought at a median value of $225.00, for a complete transaction of $131,850.00. Following the completion of the sale, the director now instantly owns 14,722 shares of the corporate’s inventory, valued at $3,312,450. The transaction was disclosed in a authorized submitting with the Securities & Trade Fee, which is obtainable by way of this hyperlink. Additionally, EVP Lance Berberian bought 12,093 shares of the corporate’s inventory in a transaction dated Monday, August fifth. The shares had been bought at a median value of $229.10, for a complete transaction of $2,770,506.30. Following the sale, the chief vice chairman now instantly owns 15,921 shares of the corporate’s inventory, valued at $3,647,501.10. The disclosure for this sale might be discovered right here. Within the final quarter, insiders bought 29,679 shares of firm inventory price $6,716,306. Company insiders personal 0.85% of the corporate’s inventory.
Analyst Rankings Adjustments
Numerous analysts have weighed in on LH shares. Truist Monetary elevated their goal value on shares of Laboratory Co. of America from $255.00 to $275.00 and gave the inventory a “purchase” score in a report on Friday, August 2nd. Piper Sandler assumed protection on shares of Laboratory Co. of America in a report on Tuesday. They set a “impartial” score and a $235.00 goal value on the inventory. Jefferies Monetary Group elevated their value goal on shares of Laboratory Co. of America from $245.00 to $265.00 and gave the inventory a “purchase” score in a report on Monday, September twenty third. Barclays elevated their value goal on shares of Laboratory Co. of America from $213.00 to $249.00 and gave the inventory an “equal weight” score in a report on Friday, August 2nd. Lastly, UBS Group elevated their value goal on shares of Laboratory Co. of America from $260.00 to $270.00 and gave the inventory a “purchase” score in a report on Friday, August 2nd. 4 funding analysts have rated the inventory with a maintain score and eleven have assigned a purchase score to the inventory. In line with MarketBeat.com, the corporate presently has a median score of “Average Purchase” and a median value goal of $253.00.
Examine Out Our Newest Report on Laboratory Co. of America
Laboratory Co. of America Firm Profile
Laboratory Company of America Holdings operates as a life sciences firm that gives important data to assist docs, hospitals, pharmaceutical corporations, researchers, and sufferers clarify and assured choices. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Companies (BLS).
Learn Extra
Obtain Information & Rankings for Laboratory Co. of America Day by day – Enter your electronic mail handle under to obtain a concise every day abstract of the most recent information and analysts’ rankings for Laboratory Co. of America and associated corporations with MarketBeat.com’s FREE every day electronic mail e-newsletter.
